Rock Springs Capital — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
City Therapeuticscitytx.comin𝕏Oct 2024
City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.
BiotechMedical DevicesCambridge, US
Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)
Co-investorsAN Venture PartnersARCH Venture PartnersSofinnova VenturesCasdin CapitalFidelity InvestmentsInvus
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.